SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10( suppl 2): S39-S53.
  • 2
    Roland M, Carlson L, Stock P. Solid organ transplantation in HIV-infected individuals. AIDS Clin Care 2002; 14: 59-63.
  • 3
    Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420.
  • 4
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247.
  • 5
    Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271-1278.
  • 6
    Radecke K, Frühauf NR, Miller M, Ross B, Köditz R, Malagó M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005; 25: 101-108.
  • 7
    Vogel M, Voigt E, Schäfer N, Goldmann G, Schwarz N, Kalff JC, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11: 1515-1521.
  • 8
    Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al.; for THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
  • 9
    de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
  • 10
    Schreibman I, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697-705.
  • 11
    Vennarecci G, Ettorre GM, Antonini M, Santoro R, Perracchio L, Visco G, Santoro E. Liver transplantation in HIV-positive patients. Transplant Proc 2007; 39: 1936-1938.
  • 12
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425-429.
  • 13
    Sociedad Española de Trasplante Hepático. Consensus document of the Spanish Society of Liver Transplantation. Waiting lists, liver transplantation and quality indicators [in Spanish]. Gastroenterol Hepatol 2009; 32: 702-716.
  • 14
    Miró JM, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005) [in Spanish]. Enferm Infecc Microbiol Clin 2005; 23: 353-362.
  • 15
    Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
  • 16
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470.
  • 17
    Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al.; for Grupo de Estudio de Sida and Consejo Asesor Clínico del Plan Nacional Sobre el Sida del Ministerio de Sanidad y Consumo. Spanish GESIDA/Nacional AIDS Plan recommendations for antiretroviral therapy in HIV-infected adults (October 2004) [in Spanish]. Enferm Infecc Microbiol Clin 2004; 22: 564-642.
  • 18
    Panel de Expertos de Grupo de Estudio del Sida; Plan Nacional Sobre el Sida. 2008 prevention of opportunistic infections in HIV-infected adolescents and adults guidelines. Recommendations of GESIDA/National AIDS Plan AIDS Study Group (GESIDA) and National AIDS Plan [in Spanish]. Enferm Infecc Microbiol Clin 2008; 26: 437-464.
  • 19
    Ayats-Ardite J, Cisneros-Herreros JM, Pérez-Sáenz JL, de la Torre-Cisneros J. Infectious disease assessment in solid organ transplant candidates [in Spanish]. Enferm Infecc Microbiol Clin 2002; 20: 448-461.
  • 20
    SEIF-88. FIPSE study on liver transplant in HIV-infected patients in Spain. https://www.seif88.com/gesida/asp/login.asp. Accessed August 2011.
  • 21
    Mandell GL, Bennet JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.
  • 22
    Busuttil RW, Klintmalm GK. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Saunders; 2005.
  • 23
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
  • 24
    Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P. Consensus document for the management of tuberculosis in solid organ transplant recipients [in Spanish]. Enferm Infecc Microbiol Clin 2009; 27: 465-473.
  • 25
    Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, Rimola A. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74: 1381-1386.
  • 26
    Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
  • 27
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al.; for European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
  • 28
    Cervera C, Agustí C, Angeles Marcos M, Pumarola T, Cofán F, Navasa M, et al. Microbiologic features and outcome of pneumonia in transplanted patients. Diagn Microbiol Infect Dis 2006; 55: 47-54.
  • 29
    Wada K, Takada T, Kawarada Y, Nimura Y, Miura F, Yoshida M, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 52-58.
  • 30
    American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
  • 31
    Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
  • 32
    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al.; for Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
  • 33
    Razonable RR, Zerr DM; for AST Infectious Diseases Community of Practice. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9( suppl 4): S97-S100.
  • 34
    Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-1284.
  • 35
    Moreno A, Cervera C, Gavaldá J, Rovira M, de la Cámara R, Jarque I, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant 2007; 7: 2579-2586.
  • 36
    Asensio A, Ramos A, Cuervas-Mons V, Cordero E, Sánchez-Turrión V, Blanes M, et al.; for Red de Estudio de la Infección en el Trasplante and Grupo de Estudio de la Infección en el Trasplante. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl 2008; 14: 799-805.
  • 37
    Griffiths WJ, Wreghitt TG, Alexander GJ. Reactivation of herpes simplex virus after liver transplantation. Transplantation 2005; 80: 1353-1354.
  • 38
    Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000; 6: 531-542.
  • 39
    Garrido RS, Aguado JM, Díaz-Pedroche C, Len O, Montejo M, Moreno A, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82: 1457-1462.
  • 40
    Knechtle SJ, Pirsch JD, Fechner JH Jr, Becker BN, Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-730.
  • 41
    Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.
  • 42
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
  • 43
    Thin L, Macquillan G, Adams L, Garas G, Seow C, Cannell P, et al. Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors. Liver Transpl 2009; 15: 421-426.
  • 44
    Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al.; for Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-1665.
  • 45
    Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): posttransplantation outcome—comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transpl 2009; 15: 79-87.
  • 46
    Bellier C, Bert F, Durand F, Retout S, Belghiti J, Mentré F, Fantin B. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int 2008; 21: 755-763.
  • 47
    Sun HY, Cacciarelli TV, Singh N. Identifying a targeted population at high risk for infections after liver transplantation in the MELD era. Clin Transplant 2011; 25: 420-425.
  • 48
    Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344: 423-428.